Washington, D.C. 20549





Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934



Filed by the Registrant  ☒                             Filed by a Party other than the Registrant  ☐


Check the appropriate box:


  Preliminary Proxy Statement
  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
  Definitive Proxy Statement
  Definitive Additional Materials
  Soliciting Material Pursuant to § 240.14a-12



(Name of Registrant as Specified In Its Charter)



(Name of Person(s) Filing Proxy Statement, if other than the Registrant)


Payment of Filing Fee (Check the appropriate box):


  No fee required.
  Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
    (1)   Title of each class of securities to which transaction applies:
    (2)   Aggregate number of securities to which transaction applies:
    (3)   Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
    (4)   Proposed maximum aggregate value of transaction:
    (5)   Total fee paid:   




  Fee paid previously with preliminary materials.
  Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    (1)   Amount Previously Paid:    
    (2)   Form, Schedule or Registration Statement No.:  
    (3)   Filing Party:
    (4)   Date Filed:







200 Broadacres Drive, 3rd Floor

Bloomfield, NJ 07003

P: 973.873.7700

F: 973.338.1430








Dear Seneca Stockholder:

Seneca Biopharma, Inc. recently has adjourned their Annual Meeting of Stockholders until September 4th. Our records indicate your vote has not yet been received.

The Board recommends you vote FOR following proposals:

· Proposal 3 – To ratify the filing and effectiveness of the amendment to the Company’s amended and restated certificate of incorporation that was filed with the Secretary of State of the State of Delaware on July 10, 2019, and the effectiveness of the 1-for-20 reverse stock split effected thereby on July 17, 2019;
· Proposal 4 – To approve an amendment to the Company’s amended and restated certificate of incorporation to authorize the Board of Directors of the Company to effect a reverse split of the Company’s issued and outstanding common stock by a ratio of not less than 1-for-2 and not more than 1-for-25, with the Board having the discretion as to whether or not the reverse stock split is to be effected at any time prior to the first anniversary date of the Annual Meeting, and with the exact ratio of any reverse stock split to be set at a whole number within the above range as determined by the Board in its sole discretion; and
· Proposal 7 – To approve the Seneca Biopharma 2020 Equity Incentive Plan and the conditional grants made thereunder to date.


Please take a moment right now to vote your shares by contacting a live representative at (866) 619-8915.





Melissa Carlson


Vice President





The Shareholder Communication Strategists

Copyright © 2020 by Alliance Advisors, LLC. ALL RIGHTS RESERVED



Seneca Biopharma (NASDAQ:SNCA)
Historical Stock Chart
From Dec 2020 to Jan 2021 Click Here for more Seneca Biopharma Charts.
Seneca Biopharma (NASDAQ:SNCA)
Historical Stock Chart
From Jan 2020 to Jan 2021 Click Here for more Seneca Biopharma Charts.